34443-04-4

Basic information

• Product Name: N-(4-hydroxyphenyl)acrylamide
• Synonyms: N-(4-hydroxyphenyl)acrylamide;N-(4-Hydroxyphenyl)propenamide
• CAS NO: 34443-04-4
• Molecular Formula: C₉H₉NO₂
• Molecular Weight: 163.17326
• EINECS: 252-026-9
• Mol File: 34443-04-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 385.9°Cat760mmHg
• Flash Point: 187.2°C
• Appearance: /
• Density: 1.231g/cm³
• Vapor Pressure: 1.65E-06mmHg at 25°C
• Refractive Index: 1.623
• PKA: 10.03±0.26(Predicted)
• CAS DataBase Reference: N-(4-hydroxyphenyl)acrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-hydroxyphenyl)acrylamide(34443-04-4)
• EPA Substance Registry System: N-(4-hydroxyphenyl)acrylamide(34443-04-4)

Safety Data

• Hazardous Substances Data: 34443-04-4(Hazardous Substances Data)

Usage

General Description

N-(4-hydroxyphenyl)acrylamide is a chemical compound with the molecular formula C9H9NO2. It is a derivative of acrylamide that contains a phenol group, which gives it antioxidant properties. N-(4-hydroxyphenyl)acrylamide is used in the production of polymers, adhesives, and coatings. It can also be used as a reagent in organic synthesis and as a precursor for the preparation of various pharmaceutical compounds. N-(4-hydroxyphenyl)acrylamide is a colorless to pale yellow solid with a melting point of 147-152°C, and it is soluble in organic solvents such as ethanol, methanol, and acetone. It is important to handle this compound with proper safety precautions, as acrylamides are known to be neurotoxic and potentially carcinogenic.

InChI:InChI=1/C9H9NO2/c1-2-9(12)10-7-3-5-8(11)6-4-7/h2-6,11H,1H2,(H,10,12)

Upstream product

• 123-30-8 4-amino-phenol 
• 79-10-7 acrylic acid 
• 814-68-6 acryloyl chloride 

Downstream Products

• 1603827-85-5 C₃₄H₄₇N₃O₁₀ 
• 1603827-86-6 C₃₀H₃₉N₃O₁₀ 
• 1603827-88-8 C₃₄H₄₈N₄O₉ 
• 1603827-89-9 C₃₄H₄₇N₄O₁₂S^(1-)*Na⁽¹⁺⁾ 
• 187147-00-8 p-acrylamidophenyl-2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside 
• 187147-07-5 p-acrylamidophenyl-2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside 
• 1603827-84-4 C₃₁H₄₁N₃O₁₀ 
• 1603827-83-3 C₄₀H₅₃N₃O₁₃ 
• 1603827-82-2 C₃₇H₄₇N₃O₁₃ 
• 1603827-81-1 C₂₇H₃₇N₃O₄ 
• 1603827-80-0 C₂₄H₃₁N₃O₄ 
• 1604244-24-7 C₃₄H₄₈N₄O₁₂S 
• 1604244-23-6 C₃₃H₄₅N₃O₁₃S 
• 1674370-85-4 C₃₃H₄₅N₃O₁₀ 

Relevant articles and documents

Improved reagents for newborn screening of mucopolysaccharidosis types I, II, and VI by tandem mass spectrometry

Tandem mass spectrometry for the multiplex and quantitative analysis of enzyme activities in dried blood spots on newborn screening cards has emerged as a powerful technique for early assessment of lysosomal storage diseases. Here we report the design and process-scale synthesis of substrates for the enzymes α-l-iduronidase, iduronate-2-sulfatase, and N-acetylgalactosamine-4- sulfatase that are used for newborn screening of mucopolysaccharidosis types I, II, and VI. The products contain a bisamide unit that is hypothesized to readily protonate in the gas phase, which improves detection sensitivity by tandem mass spectrometry. The products contain a benzoyl group, which provides a useful site for inexpensive deuteration, thus facilitating the preparation of internal standards for the accurate quantification of enzymatic products. Finally, the reagents are designed with ease of synthesis in mind, thus permitting scale-up preparation to support worldwide newborn screening of lysosomal storage diseases. The new reagents provide the most sensitive assay for the three lysosomal enzymes reported to date as shown by their performance in reactions using dried blood spots as the enzyme source. Also, the ratio of assay signal to that measured in the absence of blood (background) is superior to all previously reported mucopolysaccharidosis types I, II, and VI assays.

COMPOSITIONS AND METHODS FOR DETECTION OF LYSOSOMAL STORAGE DISEASE

The present invention provides compositions for performing assays of enzyme activity associated with lysosomal storage diseases. The invention further provides methods for determining enzyme activity, and methods for the screening for lysosomal storage disease in an individual.